Business Wire

CA-BIOCELL-TECHNOLOGY

13.6.2019 02:53:04 CEST | Business Wire | Press release

Share
BioCell Technology Announces BioCell Collagen® Skin Aging Clinical Trial Poster Presentation at ASN Nutrition 2019

BioCell Technology, LLC, a branded dietary ingredient supplier, today announced the presentation of The Effects of Skin Aging Associated with the Use of BioCell Collagen® in Healthy Adult Females: A Randomized, Double-blind, Placebo-controlled Clinical Trial . These results were presented in a poster session at the American Society for Nutrition (ASN) Nutrition 2019 on June 9, 2019, and are available at http://bit.ly/2WzhODi . This poster will be published as part of the proceedings of Nutrition 2019 by ASN. The manuscript of the study will be published in the online and print versions of the peer review journal Alternative Therapies in Health and Medicine (ATHM).

The goal of the study was to determine if a correlation existed between the effects of the dietary supplement, BioCell-Collagen®, with changes associated with skin aging. The study was a 128-female subject, 12-week, double-blind, placebo-controlled trial. Participants were randomly assigned to an intervention or a placebo. The intervention consisted of twice daily 500mg oral administration of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract dietary ingredient composed of a naturally-occurring matrix of collagen type-II peptides (≥300 mg), chondroitin sulfate (≥100 mg), and hyaluronic acid (≥50 mg).

For the 113 participants completing the study, BioCell Collagen® supplementation compared to a placebo resulted in:

  • Significantly reduced facial lines and wrinkles (P = .019) and crow’s feet lines and wrinkles (P = .05)
  • Increased skin elasticity (P = .008) and cutaneous collagen content (P < .001) by 12%
  • Improved indicators associated with a more youthful skin appearance based on visual grading and wrinkle width (P = .046)
  • Decreased skin dryness and erythema.
  • No difference existed between the supplement and the placebo for skin surface water content or retention. The supplement was well tolerated, with no reported adverse reactions.

“We are very excited to publish the findings of our largest study to date, which further supports the efficacy of our flagship dietary ingredient BioCell Collagen®. Human clinical studies continue to be the gold standard for substantiating dietary supplement claims and we take pride that our licensed partners can take advantage,” said Suhail Ishaq, president of BioCell Technology.

The latest study validates an earlier pilot study that demonstrated similar results- Schwartz SR, Park J. Ingestion of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial aging signs. Clin Interven Aging . 2012; 7: 267-273.

“An impressive example of how a series of studies, capped by a randomized, double-blind, placebo-controlled, supports a ‘beauty from within’ claim in healthy women. Even more impressive was that the results remained statistically significant even after an intention-to-treat analysis was performed that included the few subjects that dropped out of the study. Such an analysis is seen in only about 15-20% of randomized, placebo-controlled blinded clinical studies published in leading medical journals,” said Alexander Schauss, PhD, FACN, CFS, Senior Director of Research at AIBMR Life Sciences, and the corresponding author.

“It is important that the supplement industry conducts research at the pinnacle of good science and this includes a double blind, properly populated study like this one,” said Stephen Schwartz, President and CEO of International Research Services, Inc.

About BioCell Collagen ®

BioCell Collagen® is a clinically tested branded dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials, including trials on safety, efficacy, and bioavailability. BioCell Collagen® is self-affirmed GRAS (Generally Recognized As Safe). BioCell Collagen® is non-GMO and free of gluten, soy, shellfish, fish, egg, milk, peanuts and sugar. BioCell Collagen® is made exclusively in the USA and Europe. For more information, visit www.BioCellCollagen.com .

About BioCell Technology, LLC

BioCell Technology is a research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information visit www.BioCellTechnology.com .

Contact:

Suhail Ishaq President of BioCell Technology, LLC 714-632-1231

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2026–2027 World Branding Awards Honours Global “Brand of the Year” Winners at Hampton Court Palace3.11.2026 21:00:00 CET | Press release

The World Branding Awards returned to honour the brands that continue to set the benchmark for excellence. The 2026–2027 World Branding Awards Ceremony took place at the iconic Hampton Court Palace, marking the 21st edition of the awards. Set within the grandeur of a historic venue, the prestigious event brought together guests from across the globe for a memorable celebration. The evening was hosted by the acclaimed BBC presenter, Hannah Gray, and was further enriched by a keynote presentation from renowned speaker Adrian Webster. Earning a World Branding Awards remains a highly distinguished achievement. Winners are determined through a rigorous evaluation process encompassing brand valuation, consumer market research, and public online voting. This year, over 105,000 consumers took part in the voting process, and more than 2,000 brands from 62 countries were nominated. Of these, less than 10 brands from each country were declared the “Brand of the Year” across the Global, Regional,

Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 19:05:00 CET | Press release

Located in one of the world’s most prestigious hospitality corridors, the acquisition of the 308-key hotel represents a major milestone in the firm’s international growth. Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisi

SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 16:52:00 CET | Press release

His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year

BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 16:03:00 CET | Press release

Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inv

Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 16:00:00 CET | Press release

Five-year agreement builds on Sceye’s successful stratospheric connectivity tests in Japan and advances full-scale deployment of HAPS as stratospheric infrastructure and a key pillar of SoftBank’s strategy for a Ubiquitous Network Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftB

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye